<SEC-DOCUMENT>0001628280-21-014157.txt : 20210721
<SEC-HEADER>0001628280-21-014157.hdr.sgml : 20210721
<ACCEPTANCE-DATETIME>20210721155008
ACCESSION NUMBER:		0001628280-21-014157
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210719
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210721
DATE AS OF CHANGE:		20210721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38599
		FILM NUMBER:		211104497

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aacceptanceoflibervantndar.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="idb80ecde3fed438aba21dc60abd57f07_1"></div><div style="min-height:35.4pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.912%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:2.7pt;padding-right:2.7pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="margin-top:0.45pt;padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-top:0.35pt;padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</font></div><div style="margin-top:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.912%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM 8-K</font></div><div style="margin-top:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.912%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5.05pt;padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)&#58; July 19, 2021</font></div><div style="margin-top:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.912%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:700;line-height:120%">Aquestive Therapeutics, Inc.</font></div><div style="margin-top:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.912%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</font></div><div style="margin-top:12.25pt;padding-left:1.67pt;padding-right:1.67pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.780%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">001-38599</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">82-3827296</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or Other Jurisdiction of Incorporation or Organization)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission File Number)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</font></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.858%"><div style="text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Commission</font></div></div><div style="display:inline-block;max-width:6.283%;min-width:5.283%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.859%"></div></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30 Technology Drive</font></div><div style="margin-top:0.1pt;padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warren, NJ 07059</font></div><div style="margin-top:0.05pt;padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(908) 941-1900</font></div><div style="margin-top:0.1pt;padding-left:3.57pt;padding-right:3.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</font></div><div style="margin-top:0.05pt;padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</font></div><div style="margin-top:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.912%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="margin-top:0.45pt;text-indent:36pt"><font><br></font></div><div style="padding-left:27pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:24.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;&#160;&#9746;</font></div><div><font><br></font></div><div style="padding-left:5.35pt;padding-right:12.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act&#58;</font></div><div style="margin-bottom:0.05pt;margin-top:0.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.466%"><tr><td style="width:1.0%"></td><td style="width:31.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.3pt;padding-right:13.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">Title of each class</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:59.82pt;padding-right:59.82pt;text-align:center;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">Trading Symbol(s)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:25.9pt;padding-right:25.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">Name of each exchange on which registered</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.82pt;padding-right:10.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Common Stock, par value $0.001 per share</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:59.82pt;padding-right:59.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">AQST</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:51.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Nasdaq Global Market</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.912%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.912%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:5.4pt"><font><br></font></div><div style="padding-left:2.7pt;padding-right:2.7pt;text-align:center"><font><br></font></div><div style="height:35.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idb80ecde3fed438aba21dc60abd57f07_4"></div><hr style="page-break-after:always"><div style="min-height:35.4pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;padding-left:5.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:109%">Item 8.01 Other Events.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:5.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 19, 2021, Aquestive Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing the U.S. Food and Drug Administration has accepted for filing the resubmission of the New Drug Application for Libervant&#8482; (diazepam) Buccal Film for the management of seizure clusters. A copy of the Company&#8217;s press release is attached hereto as Exhibit 99.1 and incorporated into this Item 8.01 by reference.</font></div><div style="padding-left:5.35pt;text-indent:36pt"><font><br></font></div><div style="padding-left:5.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:109%">Item 9.01 Financial Statements and Exhibits.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d) Exhibits.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.382%"><tr><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex991_acceptanceoflibervan.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">99.1</a></font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Press Release, dated July 19, 2021, the U.S. Food and Drug Administration has accepted for filing the resubmission of the New Drug Application for Libervant&#8482; (diazepam) Buccal Film for the management of seizure clusters.</font></div></td></tr></table></div><div style="padding-left:5.35pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:5.35pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div id="idb80ecde3fed438aba21dc60abd57f07_7"></div><div style="margin-top:3.7pt;padding-left:141.87pt;padding-right:141.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.952%"><tr><td style="width:1.0%"></td><td style="width:57.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; July 19, 2021</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aquestive Therapeutics, Inc.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; A. Ernest Toth, Jr.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. Ernest Toth, Jr.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Title&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:35.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991_acceptanceoflibervan.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5148346242a54e218e8b944a6d318bdd_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="imagea.jpg" src="imagea.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant&#8482; (diazepam) Buccal Film </font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Prescription Drug User Fee Act (PDUFA) Target Goal Date set for December 23, 2021</font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">If approved by the FDA for U.S. market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters </font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WARREN, N.J., July 19, 2021 -- Aquestive Therapeutics, Inc. (NASDAQ&#58; AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients&#8217; unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of the New Drug Application (NDA) for Libervant&#8482; (diazepam) Buccal Film for the management of seizure clusters.  The FDA has assigned a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) target goal date of December 23, 2021. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We are pleased with the FDA&#8217;s decision to accept for review the Libervant NDA.  We believe this  underscores the unmet need in the underserved population of refractory epilepsy patients for a non-invasive and innovative product for the management of seizure clusters,&#8221; stated Keith Kendall, Chief Executive Officer of Aquestive. &#8220;We are preparing for the commercial launch of Libervant, if approved for U.S. market access, in the first half of 2022 and remain committed to fill this unmet need and improve the quality of life for patients suffering from this disease with this first of its kind treatment option.&#34;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Aquestive received a Complete Response Letter (CRL) from the FDA in September 2020, completed a Type A meeting with the FDA in November 2020 and received further guidance from the FDA in February 2021.  Based upon the Agency's guidance, the submission included additional statistical modeling and supporting analyses of the existing clinical data.  The Company continues to believe that no additional clinical studies will be required for FDA approval of Libervant for U.S. market access.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">About Libervant</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company believes that Libervant, if approved by the FDA for U.S. market access, will enable a larger share of patients to receive more appropriate treatment by providing consistent therapeutic dosing in a non-invasive and innovative treatment form for epileptic seizures.  Libervant&#8482; is a buccally, or inside of the cheek, administered soluble film formulation of diazepam, a benzodiazepine intended for rapid treatment of acute uncontrolled seizures in selected, refractory patients with epilepsy on stable regimens of AEDs who require intermittent use of diazepam to control bouts of increased seizure activity. Aquestive is developing Libervant as an alternative to Diastat (diazepam rectal gel), the current standard of care rescue therapy for patients with refractory epilepsy which, as a rectal gel, is invasive, inconvenient, and difficult to administer. As a result, a large portion of the patient population does not receive adequate treatment or foregoes treatment altogether. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">About Aquestive Therapeutics</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan&#174; (clobazam) oral film, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm&#174;, and has proven capabilities for drug development and commercialization.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Forward-Looking Statement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release includes &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement of Libervant, including our belief that the resubmitted NDA addresses all of the issues raised in the CRL, through the regulatory and development pipeline and business strategies, market opportunities, and other statements that are not historical facts.  These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials&#59; on regulatory submissions and regulatory reviews and approvals of our product candidates&#59; pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution&#59; sale of and demand for our products&#59; our liquidity and availability of capital resources&#59; customer demand for our products and services&#59; customers&#8217; ability to pay for goods and services&#59; and ongoing availability of an appropriate labor force and skilled professionals.  Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials&#59; risk of delays in FDA approval of  Libervant or failure to receive approval or U.S. market access&#59; ability to address the concerns identified in the FDA&#8217;s CRL for Libervant&#59; risk of our ability to demonstrate to the FDA &#8220;clinical superiority&#8221; within the meaning of the FDA regulations of Libervant relative to FDA-approved diazepam rectal gel and nasal spray products including by establishing a major contribution to patient care within the meaning of FDA regulations relative to the approved products as well as risks related to other potential pathways or positions which are or may in the future be advanced to the FDA to overcome the seven year orphan drug exclusivity granted by the FDA for the approved nasal spray product of a competitor in the U.S. and there can be no assurance that we will be successful&#59; risk that a competitor obtains FDA orphan drug exclusivity for a product with the same active moiety as any of our other drug products for which we are seeking FDA approval and that such earlier approved competitor orphan drug blocks such other product candidates in the U.S. for seven years for the same indication&#59; risk in obtaining market access for Libervant for other reasons&#59; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations)&#59; risk of development of our sales and marketing capabilities&#59; risk of sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer term cash requirements and other cash needs, at the times and in the amounts needed&#59; risk of failure to satisfy all financial and other debt covenants and of any default&#59; our and our competitors&#8217; orphan drug approval and resulting drug exclusivity for our products or products of our competitors&#59; short-term and long-term liquidity and cash requirements, cash funding and cash burn&#59; risk related to government claims against Indivior for which we license, manufacture and sell Suboxone&#174; and which accounts for the substantial part of our current operating revenues&#59; risks related to the outsourcing of certain marketing and other operational and staff functions to third parties&#59; risk of the rate and degree of market acceptance of our product and product candidates&#59; the success of any competing products, including generics&#59; risk of the size and growth of our product markets&#59; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities&#59; risks associated with intellectual property rights and infringement claims relating to the Company's products&#59; risk of unexpected patent developments&#59; the impact of existing and future legislation and regulatory provisions on product exclusivity&#59; legislation or regulatory actions affecting pharmaceutical product pricing, reimbursement or access&#59; claims and risks that may arise regarding the safety or efficacy of the Company's products and product candidates&#59; risk of loss of significant customers&#59; risks related to legal proceedings, including patent infringement, investigative and antitrust litigation matters&#59; changes in government laws and regulations&#59; risk of product recalls and withdrawals&#59; uncertainties related to general </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">economic, political, business, industry, regulatory and market conditions and other unusual items&#59; and other uncertainties affecting the Company described in the &#8220;Risk Factors&#8221; section and in other sections included in our Annual Report on Form 10 K, in our Quarterly Reports on Form 10-Q, and in our Current Reports on Form 8-K filed with the Securities Exchange Commission (SEC). Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">PharmFilm&#174;, Sympazan&#174; and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.  All other registered trademarks referenced herein are the property of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Investor Inquiries </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Westwicke, an ICR Company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Stephanie Carrington </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">stephanie.carrington&#64;westwicke.com </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">646-277-1282</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
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MIDB#Z-#=W=S0L6T[=&K7'IX>'L(A(&M^J157WPJEM7R\:!%4*A4<[.R@T6A
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M+]=(W!X6/$3\C_&,0G+(U)1EEA17HLNLG5#9;9(5:>8L*)5@UVK!/L0GY?&
M3_MS2)T-JZ71XKTL*52P3CL/-08OC<;%)+I\,%YG4<A#Q(?\%5UY45A!29HH
M*9UH.Z4Y_S$;IBJ5X,,T&KBZN/ !("7T[=6+V2#YQR$#!_+F[ @.YGZ+__89
M6S&QWL$#!K)R6[=HB1%65C(I(B0@RR<2TK]/'_9]-M;63,:F3)K$L2&').W;
MP]G1"536NV=/=@>KO5?S. 2S1-)H'>1SI>3MY<5ETZ9.%8N$]1#I(79,!Y36
M3Z&8E"Y=NL0H1.Z&+-3!U@X4PY(;HO"'KP7%2P3YLD&V3/$28?V^*U"-W2##
MK 2Y9*EDH>;.6S'?_Q2.G$G&I?@LG+V<#L_M<3AX6O ;I65/,&7M95BOH%N@
M6#AX"-=Y!+7SMUY'<9F&E2-!!"F*F.D[;T_E_--//_%ZI'KI285145&8,FDR
MIDYY&PD)B:BIJ<4:GS4<WY'/L1XWCF/%/[T[#2V;6X!8,*6*RDIX>WEC[.C1
MH';D ^?,GH/$Q"1Y+'JY<.$"B(A03$B*(A]*F[AKYRY45]=PB$%Q7]]>O7F#
MQXT=RW%N964ERR&+^ORSQ<QZHQ3QZ=X]>QGZO3P]Y9B2.OSZZWW,F?T^ICA/
MPK9MV^2YT)HI$2)\\O''&#UB),^'#IF-]7BL^V(=$S+:.ZDM=S JT\ 7X(_+
MJS#XP[U,?@2H%2"7E&KF' 25TQ:HK .$;+<)*MLOH1KNCS[SOH'FL>"[(J_F
M8AC%F^["13M=LMMXQ2$CCV#::)5D=70S0_"D3#($2U L/I5MZ):$9%$J+2W!
MW9P<:#3"C<W4R5-@86Z.[5]_K>R"\O(R;O>P0"!C5"G<# G_YB(U+BHLY'8%
M#QY 6R>&5.*5'8U+1"KW[EU45%1(7=AMZ+1"6RJ4;G;HID<B9F1!\DV42"AE
M 6QE"O>C^'1&7XUH?30N63_+UVGY%HGVJDG+Y H /][,10LB/@JX90LER'46
MR9'S5IA,#(()_7;>RNPW])S L.@"WN=H,H8NB8:#AQK#7,XA[+* ^ZRH!@1*
M@E%A$YX>RRK;2:=2N 8S;@G%@V]/GL)P26&&)+-A.ZE<LGSI*1T0H\3ZE_O*
M\J9D2/72_$BN/&_1DJ2QZ"DE97MEO=Q7:L@'I?X>*:J,EP92_$B5X>=38>ZP
M&2J;C4U"+EDM6ZM(E%3C-\+)-816SK(UFEHL_28!O?[S.W@?3.+3PQ^F&[!@
MY<2?]9T&)F5.='2"B4J%?VS[BN?RK')?]OZ\2/&/? -DA#?AMC[ZAW18S@B&
M:NQZAE<EPU7Z4GIG*[7?A/]*D)B7'IK'U=@:^=\H>%C!7UR,\IN.59^UGJR*
M8)&"<Z+V>W8+L=ZSRGW9^S>&V8;F6R<H-.]>*3Y:=QHFCD$<MK"/=-HB0BS!
M;!!4$X.@(BL>ZH<97A&R%<J#D#7REY;Z\/ B3CQ99EE9.?^G GU9>!%CO&PR
M_Q?+%#]1*9SPSRGWL&);#(8MV >+*=N@LM_$$"PIM^O,'7AG10@.GTEF)R^'
M%M*GK@9DYD6>=N7B7N0X+XMLV6AD-DO<4/P4T_"I;*RMKD-&7@FNIOR*BPEY
MN)24CY_3"E!<_%C>0_*-0A8^[324]^KW\]T7I7YDGREKX]7+'W8'7BGS#ZNZ
8QA/_'^ZWT1)*EM@7     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
